Responsive image

Common name


(4aS,8aS)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline

IUPAC name


(4aS,8aS)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline

SMILES


N1CC2C(CC1)CCCC2

Common name


(4aS,8aS)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline

IUPAC name


(4aS,8aS)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline

SMILES


N1CC2C(CC1)CCCC2

INCHI


InChI=1S/C9H17N/c1-2-4-9-7-10-6-5-8(9)3-1/h8-10H,1-7H2/t8-,9+/m0/s1

FORMULA


C9H17N

Responsive image

Common name


(4aS,8aS)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline

IUPAC name


(4aS,8aS)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline





Molecular weight


139.238

clogP


2.209

clogS


-1.939

Frequency


0.0007





HBond Acceptor


0

HBond Donor


1

Total Polar
Surface Area


12.03

Number of Rings


2

Rotatable Bond


0

Drug ID Common name Structure CAS Compound class Therapeutic area
FDBD00108 Nelfinavir Responsive image Protease Inhibitors; HIV Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
FDBD01076 Saquinavir Responsive image Protease Inhibitors; HIV Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.
2 , 1
FRAGNAME PDBID SIMILIRITY XSCORE SMILE HAC
3cyx_ligand_1_10.mol2 3cyx 1 -6.89 C[N@H+]1CC[C@@H]2CCCC[C@@H]2C1 11
3ekq_ligand_1_10.mol2 3ekq 1 -6.86 [N@@H+]1(CC[C@@H]2CCCC[C@@H]2C1)C 11
3el0_ligand_1_0.mol2 3el0 1 -6.86 [C@@H]12[C@@H](CCCC1)CC[N@@H+](C2)C 11
4qgi_ligand_1_9.mol2 4qgi 1 -6.86 [N@@H+]1(CC[C@@H]2CCCC[C@@H]2C1)C 11
2pyn_ligand_1_0.mol2 2pyn 1 -6.85 C[N@H+]1CC[C@H]2[C@H](CCCC2)C1 11
3d1y_ligand_1_10.mol2 3d1y 1 -6.85 C[N@H+]1CC[C@@H]2CCCC[C@@H]2C1 11
3ekx_ligand_1_0.mol2 3ekx 1 -6.84 [C@@H]12[C@@H](CCCC1)CC[N@@H+](C2)C 11
1hxb_ligand_1_9.mol2 1hxb 1 -6.82 C[N@H+]1CC[C@@H]2CCCC[C@@H]2C1 11
2q64_ligand_1_0.mol2 2q64 1 -6.82 [C@@H]12[C@@H](CCCC1)CC[N@@H+](C2)C 11
546 , 55